Power to the Patients
Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
November 5, 2025
In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could revolutionize neurological disease treatment.
In this episode of Power to the Patients, host Brandon Li speaks with Dr. Joseph Palumbo, Chief Medical Officer at BioVie Pharma, exploring the fascinating journey from academic research to pharmaceutical development, with a particular focus on neurodegenerative diseases and the crucial role of inflammation-focused treatments in brain health.

What You'll Learn:
- How successful drug development bridges academic research, clinical practice, and commercial strategy

- The key differences between developing drugs in big pharma versus biotech environments

- Why inflammation is emerging as a critical factor in treating neurological conditions like Alzheimer's and Parkinson's

- How to validate early-stage drug development data and make informed decisions about progression

- The evolution of ALS treatment and why smaller, focused trials can lead to breakthrough therapies

- Why systems biology and cross-disciplinary approaches are revolutionizing neuroscience research

- The importance of combining clinical experience with research expertise in drug development

- How natural brain molecules can be modified to create more effective treatments for neurological disorders

- Why understanding the gut-brain connection is crucial for treating neurodegenerative diseases

- The critical role of scientific collaboration and diverse thinking in advancing medical research


About the Guest:

Dr. Joseph Palumbo is the Chief Medical Officer and Head of R&D at BioVie Pharma, bringing extensive expertise in neuroscience, psychiatry, and drug development. With a distinguished career spanning academia (Yale, Cornell, University of Pennsylvania) and pharmaceutical leadership roles at Johnson & Johnson, Mitsubishi, and Cephalon, Dr. Palumbo has been instrumental in developing breakthrough treatments for conditions including ALS, depression, and neurodegenerative disorders. He played a pivotal role in bringing edaravone to market for ALS treatment after a 20-year gap in therapeutic advances. Currently leading research initiatives at BioVie, Dr. Palumbo focuses on inflammation's role in neurological conditions, particularly in Alzheimer's and Parkinson's disease, while exploring innovative approaches to drug development using systems biology and natural brain molecules.


Episode Resources:

Transcript

Brandon Li 0:00 This is gonna work. I think this is great. Okay. So, um, uh, this is also being kind of recorded and will be edited after the fact. So, like, this conversation right now, uh, will probably be, uh, snipped out. Um, I'll, uh, I'll give you a second to introduce yourself probably, and then we'll we'll kinda jump in from there. How does that sound?

Joseph Palumbo 0:17 Sounds good.

Brandon Li 0:18 Cool. Um, well, Joe, thank you so much for taking the time to have this conversation. I've been, uh, so looking forward to it.

Joseph Palumbo 0:25 Thank you, Brandon. I'm Joseph Palumbo, and I'm the chief medical officer and head of r and d at BioV Pharma, a biotech that's based in both California and Las Vegas. Excuse me. Let me start again.

Brandon Li 0:41 Yeah. Go for it. Alright.

Joseph Palumbo 0:46 Hi, Brandon. Joseph Colombo, and I'm really glad to be here. I'm the chief medical officer and the head of r and d at BioVee Pharma. Uh, we're a small biotech, uh, with headquarters in Nevada. We have folks working in a lab, uh, in San Diego, and I'm located on The US East Coast.

Brandon Li 1:04 Yeah. Lovely. Joe, uh, maybe give me just a thumbnail sketch of your career. How how did you end up at BioVee doing this work? d d at BioVee Pharma. Uh, we're a small biotech, uh, with headquarters in Nevada. We have folks working in a lab, uh, in San Diego, and I'm located on The US East Coast. Yeah. Lovely. Joe, uh, maybe give me just a thumbnail sketch of your career. How how did you end up at BioVee doing this work?

Joseph Palumbo 1:11 Well, it's been a wonderful trip. And, uh, so I started out as a psychiatrist. I had done my training at Yale in New Haven and Medical School in Washington, DC in George Washington. And I had always been interested in research, interested in brain function, had, uh, worked in laboratories, had done work in in in nerve system degeneration and and regeneration. Uh, so I had an absolute fascination, uh, with how the brain works and and the anatomy of the brain. Uh, also was very interested in in cognition, how people think, how people perceive. Um, and when I was in my residency and fellowship, I had the opportunity to pursue some groundbreaking research, which was which was tremendous at the time. Um, I had the opportunity to move into into pharma after career in academia, uh, which had me on faculty at Yale and Cornell and University of Pennsylvania. Uh, started working in orphan diseases, including ALS. Uh, spent time in, uh, biotech early in my career at a company called Cephalon, which, uh, was successful in treating disorders in sleep. Uh, moved into French pharma and lived in Paris part of the time, learned a lot about a number of disorders, uh, in psychiatry, neuroscience, Eventually ended up at Johnson and Johnson at Johnson and, uh, spent about ten years there eventually becoming, uh, the global head of psychiatry, the acting head of of neuroscience. I happen to be half Japanese. An opportunity came up came up to work for Mitsubishi, uh, as they were expanding into The United States. I started there, uh, working in renal disorders, uh, spent time working, uh, in neuroscience, of course, uh, was able to get a drug approved in the treatment of amyotrophic lateral sclerosis ALS or Lou Gehrig's disease, uh, and then moved to Japan where I worked broadly across the entire portfolio, both in in commercial and spent 20% of my time in a laboratory again, uh, which was really a lot of fun to get back, uh, to those roots. Worked across all of the disciplines, all therapeutic areas in that company, um, and then moved back to The States, uh, after that period of time. Uh, returned to work I had done in the past in, uh, neurodevelopmental disorders. Uh, we did some great work there. And then I met, uh, Kang Do, the CEO of BioVie, who told me about the molecules, about his vision, uh, as a philanthropist for how he wanted to move the company forward. And that was about four years ago, uh, and and now I'm here. So that's the quick time.

Brandon Li 4:05 Yeah. Uh, so having seen the the kind of breadth of large pharma, small pharma, biotech, um, I'm curious. What, uh, what stands out as being meaningfully different, um, developing drugs at a biotech versus at J and J, for example? ur years ago, uh, and and now I'm here. So that's the quick time. Yeah. Uh, so having seen the the kind of breadth of large pharma, small pharma, biotech, um, I'm curious. What, uh, what stands out as being meaningfully different, um, developing drugs at a biotech versus at J and J, for example?

Joseph Palumbo 4:20 It it's obviously all very, very different. Uh, a small company has to be extremely nimble. Your decision making processes are very fast. You're very much the face of the company for for good things and and and for challenges. Um, and we work closely with a with a team, with a very small team. So it's fast, uh, it's quick paced, uh, and you you you're always involved. You you you can't really take time or day off. Um, big pharma is, of course, very different. Big pharma works, uh, in some ways, like government. Um, there are a lot of friends to make. There are a lot of agreements to get to. Um, you're spending money, and, typically, it's it's a lot of money. Um, it makes things slower. It makes things more deliberate. Uh, it means bringing in many more partners. Uh, so it tends to be expensive, slower, uh, requires a great deal of, uh, of a different kind of dedication, a dedication to knowing, uh, what's happening in the field and bringing an entire company along with you. Uh, biotech is it requires many, many, many of the same skills, but you have to be actually able to outmaneuver, uh, the the larger forces. It's it's more like, you know, working with drones. Right? You have to be fat or be small. You have to be accurate as opposed to, you know, running a battleship or an aircraft carrier because it it it's it's those kinds of odds. Uh, big companies tend to, um, move, you know, like an aircraft carrier. They are they are certain, uh, but they're a little bit slower, but they're enormously powerful. And smaller companies were always looking for a way to be successful, a way to, uh, get patients, uh, the best drugs, the best treatments as quickly as as as possible, um, and do, uh, very directly, uh, benefit the shareholders is clearly you know, they're a biz these are both businesses, but with a smaller company, you're very much more aware of who, you know, who's, uh, who's supporting you, and and we take that quite seriously.

Brandon Li 6:49 Do you do you miss, running larger programs and portfolios, um, like you were at J and J versus focusing on, um, you know, individual, like, assets? s, but with a smaller company, you're very much more aware of who, you know, who's, uh, who's supporting you, and and we take that quite seriously. Do you do you miss, running larger programs and portfolios, um, like you were at J and J versus focusing on, um, you know, individual, like, assets?

Joseph Palumbo 7:05 I miss the big teams. Um, I I I miss the day to day camaraderie of having a group of people who, uh, who work together well in those larger organizations. I I had set up J and J in many ways as if it were an academic department. We brought in people who, of course, were research oriented, uh, and people who also could more than hold their own, uh, with the the commercial needs of an organization. Uh, it's it's very easy to be smart. It's much harder to be collaborative. Uh, and once you find those exceptional collaborators, uh, and you see them in person and you have lunch with them every day, uh, that's an absolute treat. That's an absolute honor. And and you can you can come up with new ideas very, very quickly when you're in a team like that. Smaller pharma is, uh, hopefully, you've made a lot of friends. Uh, and we hope that those friends will still collaborate with you, uh, so it's a lot more active. The folks aren't just sitting there at your elbow with a lunch table. You have to go out and reach them. Um, so I I miss that easy access, uh, to lots of on the other hand, I've been lucky enough to to make good friends over a career, and I reach out to to those wonderful folks as as ever whenever I can, uh, to help within a smaller company.

Brandon Li 8:37 Yeah. Maybe maybe take me into the inside the story around your work in ALS. Sure. I'd love I'd love to I'd love to hear more about what that was like and, uh, the kind of, um, process of, uh, of working in that space. derful folks as as ever whenever I can, uh, to help within a smaller company. Yeah. Maybe maybe take me into the inside the story around your work in ALS. Sure. I'd love I'd love to I'd love to hear more about what that was like and, uh, the kind of, um, process of, uh, of working in that space.

Joseph Palumbo 8:56 So when I first came to ALS, I knew very, very, very little about the field. I was a well trained neuroscientist. I was, uh, well trained in cognition and and disorders of the brain, disorders of the mind. But despite the work I had done in the laboratory, I I didn't know motor systems nearly as well, and I and I certainly didn't know inflammation, uh, at the time as well as I did. Uh, I've learned over over the years. So it took friends. Right? It it it took colleagues. It took mentors. So my first attempt at at ALS was working with another, uh, wonderful biotech. And, again, that a company was Cephalon, and they were located in Pennsylvania. And that's one of the you know, it was a hotbed, uh, the Pennsylvania area of neuroscience at the time. Um, and there were terrific people, including the CEO. A guy who sadly has passed on, but was absolutely brilliant and committed, uh, to science and patience. His name was Frank Baldino. Um, and Frank asked me to to start working in ALS. Uh, we had a program there, uh, with at least one positive study. Um, uh, the drug was called myotrophin, and, uh, Frank enabled me to go and work with some of the the great professors. And, uh, there are many people, and I know that I'll leave out some names. One of the people, uh, was doctor Stan Appel, and doctor Appel had moved from Boston, uh, to lead a program in Texas. And he invited me in to spend time with him and learn what he did, uh, to work with patients, and, um, he enabled me to learn a lot more than I had. Um, and he introduced me to a group of global experts. Now, ultimately, that program, uh, didn't succeed, uh, in in in registration. But when I came to Mitsubishi, I had had bad experience, um, working in ALS, and it was literally twenty years later. Uh, I discovered that there was a program that was ongoing with medical experts in Japan that appeared to have promise. Uh, it really wasn't on anybody's radar. Uh, so I watched it very carefully. And as the the data began to come out, I gathered it, uh, with my Japanese colleagues, and I went back to the same group of experts I had met twenty years earlier. Because I wanted to make sure that this was a molecule, this was a compound, this was a treatment that would really work. So I asked these folks, uh, doctor Appel and others, Terry Hyman Patterson in Philadelphia, a group of folks who really, really cared about patients. Does this data look real? Does it can can you can you say that this is a molecule that is working? And I said, yeah. It appears to be working. So, uh, at Mitsubishi, we put together a team of Americans and Japanese, worked very closely with the US FDA, uh, gathered data, some of which at that time were soft floppy disks and written in in workbooks, uh, translated that into English. Uh, and then we were successful in very rapidly bringing forward an an intravenous product. Uh, and shortly thereafter, uh, we knew that the intravenous product was going to be helpful, but we wanted something that was easier to take. So we were very, very rapidly on an oral formulation, and we're able to get that approved. But, uh, working with people across the country, um, and across the world, uh, on something, you know, really this meaningful. And there there hadn't been a drug to come forward in over twenty years at the time. There was only one, uh, a drug called bromeliadsol, certainly, uh, was effective in in in slowing, uh, the disease. What we were able to do through the work that we did was we were able to preserve function for longer. Uh, and and that's hard. That's that's hard because when you take a drug, you don't necessarily notice that you're getting better because you're you're probably not. You don't notice much, but we can look at the course of an illness and know that if you had not been taking the medication, you would have been progressing more rapidly. Um, and people hadn't done that kind of projection often, uh, in neuroscience. It would take another ten years or so before the Alzheimer's community, uh, was able to bring forward molecules that slowed progression of disease and preserved function. But we were there early, and and frankly, we had very, very cooperative and cooperative's not the word. A a a a very engaged group of scientists at the Food and Drug Administration in The United States and Japan and other countries, uh, who recognized, uh, that there was need. Uh, US and Canada were particularly, uh, engaged in this way, Japan as well. rankly, we had very, very cooperative and cooperative's not the word. A a a a very engaged group of scientists at the Food and Drug Administration in The United States and Japan and other countries, uh, who recognized, uh, that there was need. Uh, US and Canada were particularly, uh, engaged in this way, Japan as well.

Brandon Li 14:31 One of the things you said, uh, kinda stuck out to me, which is, like which was the the, I guess, scientific diligence process you went through, just trying to understand, like, how real is this data?

Joseph Palumbo 14:44 Yes.

Brandon Li 14:46 I, uh, I feel like everyone is doing that. Right? Like, um, in biotech land, everyone is trying to do that. Um, what what what do you think you've seen, um, that points towards, hey, this is this is truly believable, um, in the earliest stages versus,

Joseph Palumbo 15:03 I

Brandon Li 15:03 don't really know if this passes my, uh, my kind of sniff test. Like, um, in biotech land, everyone is trying to do that. Um, what what what do you think you've seen, um, that points towards, hey, this is this is truly believable, um, in the earliest stages versus,

Joseph Palumbo 15:03 I

Brandon Li 15:03 don't really know if this passes my, uh, my kind of sniff test.

Joseph Palumbo 15:07 Yeah. It's it's really a very difficult question. And the reason it's difficult is because so many things that look really, really good in the computer or really in the animals, uh, sometimes doesn't work out in the human condition, and sometimes we never learn why. Um, some of the work I'm doing now, you can probably talk about later, uh, is based on that duality between animals and and and and humans. But to make sure that something's really working, you you wanna create an experiment set up to answer a particular question, and then you need to be able to replicate that. Right? So FDA typically looks for at least two studies, right, to prove that something works, and then they, you know, do this to a degree of statistical significance. In other words, it's only 5% unlikely that this could have happened by chance. So it's 95% certain. They need that twice. And then, typically, they may ask you for additional studies after the drug is on the market, and that's just very much the minimum. What the scientists had done in Japan is they had taken this drug, edaravone, and they had shown that it worked very well in ischemic stroke, and it had become the standard of care in Asia for the treatment of stroke. And there were a group of very dedicated scientists, physicians, and and and other folks who said, you know, can we try this drug that we know to be effective in stroke and we know to be safe in stroke and see if it works in ALS. And so they did that, and they conducted a trial, and it didn't quite work. And then they conducted another trial, and they changed the inclusion criteria and the dosing, and they finally got it right. And then they said, okay. Let's repeat that experiment. Let's enrich that. Let's confirm that what we saw in this last experiment prospectively studied is really true, and they did that. And they did it with a different kind of trial design, which was what was very much enriched for patients who were progressing. Um, when you do things like that, when you do this enrichment, it's important to understand whether or not that enrichment is generalizable to a larger population. Why that's so important in a in a disorder like ALS is because it's an orphan condition. So you have people who have the disorder. They're they really want to participate in research. Frankly, they're trying to help others who have the disorder. The ALS community is extremely strong that way, and you have to move pretty quickly. In the past, and and this is actually still true in Europe, they wanted studies the scientific community, they, meaning the scientific community, wanted studies that ran several years, which meant large studies, lots of patients, and it might take four, five, six years for a drug to be, uh, to be studied. And by that time, the folks who had largely started in the study would have passed away. So we're looking at time, frankly, time to death. What we wanted to do is look at function, and we wanted to try to get these studies to be much shorter. We wanted them to be smaller. So we did things differently. I guess if if there's anything that I'm particularly proud of is working with those Japanese scientists to bring this concept of enrichment to The United States doing faster, smaller studies and then repeating them Mhmm. In order to get a drug approved. Now because that was something that was new, I needed to make sure that when I took this to the experts in the community, the people who really knew this disorder, the folks I had met twenty years earlier, that they see what I saw. Right? And and that was that extra step. And this meant that the FDA was going to be judging this program based on history in Asia, in in stroke, as well as what the scientists had done in Japan and to enable us to bridge that into The United States. And now we got a lot of assistance in figuring out exactly how to do that. We published on, uh, these aspects of the disorder and the aspects of the medication. Um, so I think everyone in biotech is trying to do these things. But I I will say that for the community and the scientists who were working for me, they were extremely careful because we we didn't wanna produce false hope. Wanted to be certain that what we saw scientifically, uh, and clinically, uh, was relevant. How do you how do k everyone in biotech is trying to do these things. But I I will say that for the community and the scientists who were working for me, they were extremely careful because we we didn't wanna produce false hope. Wanted to be certain that what we saw scientifically, uh, and clinically, uh, was relevant. How do you how do

Brandon Li 20:18 you balance the desire to do that with, um, I mean, everybody talks about timelines, right, and and speed and all this kind of stuff. How do you balance the desire to, um, really take your time and make sure you you've kind of, uh, validated everything to your best ability versus, um, maybe the the

Joseph Palumbo 20:35 kind

Brandon Li 20:35 of, uh, like, shareholder, like, or investor dynamic of wanting you to, um, go as quickly as possible.

Joseph Palumbo 20:44 Yeah. I mean, some people will say go as fast as you can and no faster. That really doesn't answer the question. Right? But people say that, and and typically scientists will do that. And and I think you really have to have a partnership with the community of experts. They need to understand what you're doing because they're gonna help you communicate to your investors. Is what these folks are doing? Does does this make sense? And then you try to be as open as you possibly can be about your progression. Um, and what you try to do is to develop a molecule to its next logical step. So you're not trying to promise everything all at once. You're trying to say, for this much money, we can deliver this endpoint. Right? Uh, and you try to publish on that, and you try to do it openly. But it's really development to your next decision point, and the next decision point is typically, have you learned something? Right? And and and what what have you learned that enables you to move on or to adapt? But you're really asking for funding to that next decision point. And I I think that's how you you do invest. Um, and we try to do that at BioVie. We've tried to show, you know, all of our data coming forward and and and to share what we what we learn.

Brandon Li 22:25 Yeah. I'd love to maybe, uh, take a maybe a step back and just talk about the the broad landscape of neuroscience right now. Um, maybe give me an overview as to, like, how you see the the kind of landscape and the current momentum and where where you're most excited. share what we what we learn. Yeah. I'd love to maybe, uh, take a maybe a step back and just talk about the the broad landscape of neuroscience right now. Um, maybe give me an overview as to, like, how you see the the kind of landscape and the current momentum and where where you're most excited.

Joseph Palumbo 22:46 It's it's never been a more exciting time, uh, to be a neuroscientist. Um, and that that probably is true every day as we learn more and more about how the brain works, how how the body works. I guess the biggest difference is that we're no longer working in the silos in which we once did. That I think there's been a generation of of of scientists, physicians, researchers who have worked across disciplines, uh, across fields, and I've been lucky enough to be able to do that, who take what's learned in oncology and say, hey. You know, there's something similar in neuroscience or what's been learned in immunology. So, you know, there's a system that looks just like that in neuroscience. And to begin to look at these as systems and and and I think when I first started doing this, there was a sort of this concept how simple of of how simple can you make it? Now I I know why we wanna make things simple because it makes it difficult. But I think there's a growing understanding that the systems biology, uh, of neuroscience is incredibly important to everything from nerve regeneration to depression. And and as that moves forward, as we see how drugs, uh, affect things like DNA methylation, right, which is essentially changing and modulating, you know, how your DNA functions in real time. With this kind of knowledge, things are extremely interesting. So, you know, we we have what are called small molecules, uh, which are sort of the typical things that you would think of when you take a pill. Like, an antibiotic is typically a small molecule. Um, and then there are these large molecules, uh, which, uh, target immune systems, typically. Uh, there are DNA therapies. There are RNA therapies. Uh, we have a host of different mechanisms now that we didn't have, and we have different folks looking at all of this very, very aggressively. Uh, and and I think that makes neuroscience particularly interesting. I guess what I I'm most interested in is this interaction between inflammation, uh, between diet, uh, between how we, uh, exist in our environment, um, the things we eat, um, and how our bodies work. Uh, and in neuroscience and these, we have a greater and greater understanding that there are things that are good for us, um, and we need to understand why those things are are good for for us. So exercise and diet matter to the development, and we accept we all understand this to say diabetes, but it hasn't been so long ago. We're frustrated to understand, well, you know, this this link with diabetes is related to a number of things, metabolic syndrome, um, but also inflammation. And inflammation and its management is extremely interesting, uh, in terms of what the future will bring to us. So, you know, thirty, forty, fifty years ago, we began to have this hunch, um, that statins, you know, were important in treating, uh, high cholesterol. I think what we understand now is we do a lot of things to our bodies that affect the vasculature, uh, that when that vasculature is inflamed, it's more likely to lead to poor outcomes. It's more likely to lead, for instance, to the development of cholesterol related illnesses. So it may not necessarily be cholesterol, it may be inflammation. And if we can manage inflammation, high blood pressure, all these sorts of of what we think of as disorders of internal medicine rather than neuroscience, turns doubt that internal medicine is incredibly important to keeping your your brain healthy. So when people ask me in general, what are the things I can do for my brain? I can see, well, you know, the things you do for your heart are also really good for your brain. So this, again, this this understanding that there are systems that we treat, rather than sort of these, I'm gonna say, monotonic interventions. Um, and that medicine is medicine regardless if it's the brain or the heart or the body or or the gut, uh, and understanding that these things all and they talk to each other and play with each with each other. And if we can find out how to facilitate those things causing you know, relating to better health, Um, that's what's exciting about neuroscience right now, and people are are are moving there in that direction. And and I think that's incredibly exciting. l and they talk to each other and play with each with each other. And if we can find out how to facilitate those things causing you know, relating to better health, Um, that's what's exciting about neuroscience right now, and people are are are moving there in that direction. And and I think that's incredibly exciting.

Brandon Li 27:50 So if if I was a, uh, a young researcher, um, where where would I go? Um, like, where where would you counsel me to go to to kind of participate in this? at's exciting about neuroscience right now, and people are are are moving there in that direction. And and I think that's incredibly exciting. So if if I was a, uh, a young researcher, um, where where would I go? Um, like, where where would you counsel me to go to to kind of participate in this?

Joseph Palumbo 28:01 Well, let's say you wanna be a physician, right, uh, as a researcher, and I think that's, you know, a a path I'll I'll walk down right now. I I think the best thing that a physician can do in learning how to be a researcher is to sit with patients and families, uh, to learn the signs and symptoms of disease and and, you know, not skip on that. We have we have a lot of folks who wanna just run to the laboratory, and I think that's that's wonderful. But I think you miss something if you're not at bedside for a number of years. It teaches you compassion. It teaches you, um, issues a lot about the human condition and about how, uh, how illnesses affect us and how to detect them. Um, so that's sort of the first step is is be be a good physician. And by being a good physician, it means that you embody all of that. It becomes a calling for you. From that place, I think it enriches your ability to do research. Um, now I'm biased. That's that's the path I took, but I think it's a good path. Um, it it helps to understand how, uh, medical systems work. It helps to understand how care is provided. So I I ran a hospital group, and I ran a hospital I actually ran a hospital. Uh, so it was important to understand, you know, what are the needs that, uh, clinicians and and administrators are going to have relative to, uh, the patients and families we need to treat and the medications and interventions we bring to bear because it all, again, is part of a different kind of system of health care, uh, and how to make these how these how these treatments are both meaningful and incredible treatments. It it means that today, we're developing drugs that we need to show have clinically relevant outcomes rather than, you know, just hitting a p value that I mentioned before, statistically significant change. We need to show that these drugs show, uh, meaningful improvement or meaningful change in the people who take them to create a a certain value because we do pay money for things, so value becomes part of this. Um, so maybe a longer answer to the question, but, uh, I I think it so so going into research, become a clinician first if that's the path you wanted as a medical doctor. Um, learn systems biology. Um, I think it's enormously helpful. People who work as engineers and then who go into medicine, uh, do exceptionally well because they ask how things work before they ask why things work. And there's a there's a subtle difference. So how things work means what are the interactions? Uh, and then the why can follow. The why helps to understand how the system works. A typical question I would get from the folks that, you know, I help to train, uh, when I when I, uh, go to conferences and I'm asked to to help mentor, people people will say, you know, I wanna be a brain scientist. That's great. What do you wanna study? Well, I wanna learn how to use an MRI, or I wanna learn how to do this kind of imaging, or I'm interested in the the the the the brain gut interaction. I said, that's great. What's the question you wanna ask? Do you have a burning question? And it doesn't have to be the quote, unquote right one, but there has to be a question because otherwise, I think you really just become a technologist. And there's nothing wrong with technology, but I think you need to ask yourself, what are the questions I'm trying to answer? What am I trying to learn? You know, how am I gonna change the practice of medicine? And and you'll go down a lot of wrong avenues. That happens. And and but but that is what I hear from I wanna learn how to use this technology. And fortunately for for that kind of thinking, technology always changes. trying to answer? What am I trying to learn? You know, how am I gonna change the practice of medicine? And and you'll go down a lot of wrong avenues. That happens. And and but but that is what I hear from I wanna learn how to use this technology. And fortunately for for that kind of thinking, technology always changes.

Brandon Li 32:31 Right.

Joseph Palumbo 32:32 Right? And and and you want technology to advance and train, but you wanna be able to use the technology to answer the questions you have.

Brandon Li 32:41 Rather than What what are the questions you're trying to answer right now? hnology always changes. Right.

Joseph Palumbo 32:32 Right? And and and you want technology to advance and train, but you wanna be able to use the technology to answer the questions you have.

Brandon Li 32:41 Rather than What what are the questions you're trying to answer right now?

Joseph Palumbo 32:46 The questions I'm trying to answer right now are related to inflammation. Uh, it it's related to this question of if you can treat inflammation, how does systems biology change, and how does it make you better? Uh, this question came to me first probably two decades ago. I was working at Johnson and Johnson. We were working with these exceptionally interesting, uh, and and wonderful folks at Emory University, but Charlie Nemeroff and other folks who were there. And the question was if you blocked TNF, which is this body makes TNF to to create and fight infection. Right? But it creates a lot of inflammation. So there's a tumor necrosis factor, but it doesn't exist only in tumors. It it exists broadly and is a chief driver of inflammation. So we used a molecule called infliximab. The brand name was REMICADE. And we looked at patients who had high levels of inflammation, and we saw that when you looked at patients with refractory major depression and you gave them a drug to stop inflammation, you know what happened? They got better. The depression went away. And this was this huge learning for the community of, wow. Right? And then I've worked with other drugs that are being developed by other companies, looking at different aspects in in in this pathway, this cascade of depression. So we're looking at at schizophrenia. We're looking at other conditions. We certainly know that if you block inflammation, you can treat certain movement disorders, motion, uh, uh, not just ALS, for instance, we showed when I was at Mitsubishi, but we learned that if you change inflammatory responses, even with natural products, uh, you can treat relapsing multiple sclerosis. That's what Mitsubishi had done in cooperation with Novartis. So, yeah, these partnerships are incredibly important, but the the point being, what I'm trying to understand right now is if you if you modulate inflammation, can you protect the brain? Right? And what are the pathways by which you do that? How do you measure that? So we're very interested in measuring changes in DNA called methylation. Right? Methylation, again, changes how a pathway will will will function. So that's when I'm really interested. So we're looking right now at at BioVie, at long COVID, seeing can we change the inflammation so that people's brain fog can go away and and so they can be less fatigued and function again? So that's a a big question we're asking with, uh, assistance from, uh, the US Department of Defense. They are extremely interested in this. Uh, we're asking that question in dementia and Alzheimer's. We're very actively asking that question in Parkinson's disease. We've shown some data in a small study that suggests that when we block inflammation, uh, with our our drug, uh, we can improve what's called motor function, the ability to move, uh, even the ability to sleep. So now we're asking, can we get in really, really early, and can we provide an assistance, uh, and maybe even a first line therapy? So so, again, the questions I'm asking are about inflammation, its effect on aging. And we have some early and very interesting information, uh, that we've recently published and then we'll be talking about in in in upcoming months, uh, on whether or not these changes we're seeing in methylation can influence the course of aging. So really, really important things. As you can tell, I'm really excited about them, um, and we want them to be safe. Right? We want them to be we want these to be treatments that treat inflammation but don't make us susceptible, uh, to infectious disease. For instance, you might think of a steroid. And steroids we take, and, yeah, they make us a little better, but they can block our ability to fight a disease. So we want drugs that are likely to change our response to inflammation but not to suppress our immune systems. And again, we're beginning to see that with some of the drugs we're developing. of a steroid. And steroids we take, and, yeah, they make us a little better, but they can block our ability to fight a disease. So we want drugs that are likely to change our response to inflammation but not to suppress our immune systems. And again, we're beginning to see that with some of the drugs we're developing.

Brandon Li 37:40 It's really interesting to hear that, like, that your primary focus is inflammation as it relates to, let's call it, like, neuroscience and psychiatry. Is there a particular reason why that's the kind of downstream, um, effect you're you're you're most interested in, um, as opposed to maybe, like, other parts of the body? Um, is there, like, a hypothesis that kinda links these two specifically, or is this just, like, by nature of your your background in training?

Joseph Palumbo 38:13 You know, it's a lot of all of that. So, yes, that's the background in training I have. Certainly, you know, I played baseball as a kid and as a young adult, so I tend to see things in terms of baseball rules. My my kids tease me that, you know, I speak of things being home runs and grand slams. So, yeah, there's a filter through which you see things as a neuroscientist, as a psychiatrist, as a bedside clinician, as a hospital administrator. It changes it changes the lens through which you see things. On the other hand, having worked across multiple therapeutic areas, you know, in in my career, uh, it helps me to look for these links. Um, there are practical matters as well. I mean, if I wanted to take this question about inflammation into, uh, metabolic disorders, uh, diabetes, etcetera. Uh, typically, these are extremely large studies that may involve thousands of people over perhaps even a decade. And if I were to really big pharma, I might consider that. But in a biotech where you typically have enough money to get through a year at a time, we need to do things that are just a little bit more focused. And that and that's in part why we're in these conditions in which the scales and the diseases are more approachable for biotech. And then you hope that what you prove there then gets noticed by other scientists, and they have the resources to expand. So there's a mix of things. Certainly, uh, these mechanisms could work in in other conditions as well, um, because inflammation isn't solely in the brain. Inflammation is everywhere. Right? Mhmm. Um, aches and pains are often inflammation, um, but you have to pick a focus because you only have so many resources. Yeah. And then you think about, you know, where do you get your biggest bang? And and for me, that's in these conditions of neuro neuroscience where there's tremendous unmet need, um, and that need isn't going away.

Brandon Li 40:44 So so maybe let's use that as a jumping off point, and I know, um, we're almost, uh, short on time here now. Um, but but tell me about, like, tell me about the the kind of inflammation hypothesis, um, in, uh, in Parkinson's and Alzheimer's where you're, uh, you're doing work today. t going away. So so maybe let's use that as a jumping off point, and I know, um, we're almost, uh, short on time here now. Um, but but tell me about, like, tell me about the the kind of inflammation hypothesis, um, in, uh, in Parkinson's and Alzheimer's where you're, uh, you're doing work today.

Joseph Palumbo 40:59 Yeah. So let me start by looking at what we believed that we've known for decades and decades about these conditions and how that's changed. So in Alzheimer's, when doctor Alzheimer himself, you know, over a hundred years ago, looked at brain tissue, he said, uh, this is a very peculiar kind of dementia. It doesn't include everyone. This is a particular kind of dementia in which when I look under the microscope, I see these things that are called plaques and tangles. And he was looking at these in a light microscope, and what what he discovered was, okay, so this is sort of the beginning of the amyloid hypothesis. What is causing this? This is this is tau. This is amyloid. And then that almost went away because we began to think, well, what are the other things that cause dementia? Is are these mini strokes? Are is this hardening of the arteries? These are only terms we used to hear about. And we thought of dementia as this very broad thing that we sometimes couldn't even diagnose until after somebody had passed. We'd have a look at the brain to discover what kind of Alzheimer's it was. Um, and then about twenty years ago, we began to think, well, you know, amyloid seems to be there a lot. Why is amyloid there? Let's let's let's see what happens if we remove the amyloid, see if we can still have the disease. And we've done that, and we've gotten about as far as I think we're gonna get with that right now. We could slow the disease a little bit, but we didn't ask what causes the amyloid. Right? So typically, when amyloid builds, it builds in reaction to inflammation. And amyloid is in part protective against further inflammation. So in a way, it's like a scar tissue. Right? So that's what we knew, but we weren't really thinking about what were the processes going on in the brain that led to this really interesting pattern of, um, and this is another little weird thing, right, is that Alzheimer's in its traditional state starts in parts parts of the brain and then grows out. So why would that kind of happen? We have to ask ourselves, okay, what was happening? Why was that happening? Um, and there were tremendous scientists beginning to work on this and saying, you know, there's a process by which the brain becomes inflamed by which there's a substance called tau, and tau breaks and fractionates, and that starts acting almost like a virus, like a and we weren't really necessarily thinking of that. So now we're thinking of it. Same with Parkinson's. So Parkinson's is this fascinating condition that we think of as, you know, or we have thought of as as simply being this loss of dopamine in the brain. Uh, and, certainly, that is true. We lose dopamine neurons. We lose them in a part of the brain, uh, called the substantia nigra, which is basically the black stuff. You know? We're going way back in history. What was not what was not working? What the black stuff wasn't there, and those were the neurons that were making dopamine and and resulted in moving. But there's something else very, very fascinating. But if you walk up to someone with early Parkinson's and you kind of get them excited about something, they can actually move. And why is that? Well, part of it is there's this, you know, the surge in dopamine, but there are also auxiliary pathways that we really haven't thought about or or we don't really pay attention to. And those auxiliary pathways, in addition to the substantia nigra, are all susceptible to inflammation. Right? And now we begin to think in the last ten or fifteen years, is there something that goes on in our guts where some kind of disease, some kind of process comes from the gut, goes to the brain, and causes inflammation, um, and then leads to dysfunction. And, I mean, you can think about long COVID. You can think about COVID when people started to lose their sense of taste, lose their tense sense of smell. Why would a virus that infects our lungs affect our ability to smell and taste? And it has to do with inflammation and inflammatory response and the activity of those viruses within the nervous system. And sometimes you don't think about that. I think Parkinson's is similar. I think that Parkinson's is in for many people, far as an inflammatory disorder. And that the natural molecules in the brain that can, again, work in the system's biology, uh, we can find ways to make them work. So very, very quickly you know? So how the drug I'm working on, I hope, is working is through this aspect of systems biology. There there are similar molecules that exist in the brain that can be modulated to treat postpartum depression, for instance. This molecule we're working with actually is, and this is a really cool thing, it is a naturally occurring brain molecule that our scientists just made a little different so that it's more stable, will last longer, you can take orally. Uh, and so that's my question. Can we get in early, use the systems biology approach using, frankly, a naturally occurring brain molecule to change the course of these two disorders. Um, and, you know, uh, I spent the last four and a half, almost five years, uh, working on this experiment. Um, and to this point, I'm pretty encouraged. Remarkable. n. Can we get in early, use the systems biology approach using, frankly, a naturally occurring brain molecule to change the course of these two disorders. Um, and, you know, uh, I spent the last four and a half, almost five years, uh, working on this experiment. Um, and to this point, I'm pretty encouraged. Remarkable.

Brandon Li 47:16 Thanks. Well, Joe, uh, maybe maybe kind of in closing here, I'd love to I'd love to hear from you. Um, what do what do most people get wrong about doing research in Parkinson's and Alzheimer's?

Joseph Palumbo 47:35 Very few people get things wrong. Okay? I if you come to Parkinson's, you come to Alzheimer's, you come to neuroscience, you're here for a reason, and the reason you're here is because you wanna get people better, at least I hope that's the reason. Right? You you wanna reduce suffering. That's the most important. If you wanna think of sort of, uh, you know, an Asian, uh, concept, a Buddhist concept, this is life is really, really, really hard. People suffer. And as scientists, as clinicians, as researchers, we wanna reduce suffering. So I don't think people really get that wrong. And if they are not coming from that position, that is wrong. Um, I would ask people to think about working with colleagues who are diverse in our thinking. Uh, put together really, really good teams. Listen to people. Listen to their concepts. Listen to their ideas if they sound a little bit wacky. Uh, because I think, you know, this systems biology is helpful in a very serious way. Look to evolutionary pathways. We sometimes don't do that. Uh, and and I I am very, very hopeful as this next generation of researchers goes into the laboratory, into the clinic, that they'll be talking across scientific boundaries. Um, and I think that's the right thing to do. Um, because I don't think there's anything wrong. I think there's just a lot more right that we can do.

Brandon Li 49:13 Yeah. I love that. Well, Joe, thanks again for taking the time today. Uh, really appreciated you, um, joining to to kinda educate me here.

Joseph Palumbo 49:20 Well, Brandon, uh, a delight, and, uh, thank you for inviting me.

Brandon Li 49:25 Of course. Alright. I'm gonna hit stop here.